United States Financial Markets News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Oops... There was a problem with your request.
- Country "se" not found.
Search entities
Discover all 32,649 supported financial entities for United States financial markets here.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 287,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "b1cc8e17-6861-41fa-ba96-62d407a7978b",
"title": "Replimune (REPL) Highlights Promising RP1 Data at ASCO 2025 | REPL Stock News",
"description": "Replimune (REPL) Group unveiled new data for their RP1 treatment at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago. The presentation c",
"keywords": "GuruFocus, Article, News, GuruFocus News, REPL",
"snippet": "Replimune (REPL, Financial) Group unveiled new data for their RP1 treatment at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago. The pre...",
"url": "https://www.gurufocus.com/news/2900263/replimune-repl-highlights-promising-rp1-data-at-asco-2025-repl-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BHIM.png?20",
"language": "en",
"published_at": "2025-06-01T22:00:59.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "REPL",
"name": "Replimune Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 67.00341,
"sentiment_score": 0.073367,
"highlights": [
{
"highlight": "<em>Replimune</em> (REPL, Financial) Gro[+305 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+295 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+271 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Replimune</em> <em>[+272 characters]",
"sentiment": 0.8834,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Replimune</em> is well-capitalized, [+133 characters]",
"sentiment": -0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Replimune</em> (REPL) Highlights Promising RP1 Data at ASCO 2025 | REPL Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "7c7b2e2d-f574-4005-898b-171fee355a4e",
"title": "Allogene Therapeutics (ALLO) Showcases Promising Data from Phase 1 TRAVERSE Study | ALLO Stock News",
"description": "Allogene Therapeutics (ALLO) revealed promising results from its Phase 1 TRAVERSE study at the 2025 ASCO Annual Meeting. This study focused on the investigation",
"keywords": "GuruFocus, Article, News, GuruFocus News, ALLO",
"snippet": "Allogene Therapeutics (ALLO, Financial) revealed promising results from its Phase 1 TRAVERSE study at the 2025 ASCO Annual Meeting. This study focused on the in...",
"url": "https://www.gurufocus.com/news/2900259/allogene-therapeutics-allo-showcases-promising-data-from-phase-1-traverse-study-allo-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BIIE.png?20",
"language": "en",
"published_at": "2025-06-01T22:00:23.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ALLO",
"name": "Allogene Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 89.619415,
"sentiment_score": 0.2227,
"highlights": [
{
"highlight": "<em>Allogene</em> <em>Therapeutics</em> [+225 characters]",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+300 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+293 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Allogene</em> <em>T[+169 characters]",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Allogene</em> <em>Therapeutics</em> [+197 characters]",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Allogene</em> <em>Therapeutics</em> (ALLO) Showcases Promising Data from Phase 1 TRAVERSE Study | ALLO Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "c34230ff-5cef-4146-b934-341bc96874f2",
"title": "Regeneron (REGN) Highlights Promising Phase 3 Trial Results for Libtayo | REGN Stock News",
"description": "Regeneron Pharmaceuticals (REGN) has unveiled comprehensive findings from the Phase 3 C-POST trial concerning Libtayo, a PD-1 inhibitor, for treating patients w",
"keywords": "GuruFocus, Article, News, GuruFocus News, REGN",
"snippet": "Regeneron Pharmaceuticals (REGN, Financial) has unveiled comprehensive findings from the Phase 3 C-POST trial concerning Libtayo, a PD-1 inhibitor, for treating...",
"url": "https://www.gurufocus.com/news/2900250/regeneron-regn-highlights-promising-phase-3-trial-results-for-libtayo-regn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000008R4.png?20",
"language": "en",
"published_at": "2025-06-01T21:45:36.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "REGN.MX",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 57.823956,
"sentiment_score": 0.124683,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+217 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+312 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+301 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+266 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+320 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+332 characters]",
"sentiment": 0.0258,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 57.822903,
"sentiment_score": 0.124683,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+217 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+312 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+301 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+266 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+320 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+332 characters]",
"sentiment": 0.0258,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0R2M.L",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 57.82254,
"sentiment_score": 0.124683,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+217 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+312 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+301 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+266 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+320 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+332 characters]",
"sentiment": 0.0258,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "589e7861-9f23-453b-9411-44199c46acb3",
"title": "Arvinas (ARVN) Announces Promising Phase 3 Trial Results for Vepdegestrant | ARVN Stock News",
"description": "Arvinas (ARVN), in partnership with Pfizer, has disclosed significant findings from their Phase 3 VERITAC-2 clinical study. This trial assessed the efficacy of",
"keywords": "GuruFocus, Article, News, GuruFocus News, ARVN",
"snippet": "Arvinas (ARVN, Financial), in partnership with Pfizer, has disclosed significant findings from their Phase 3 VERITAC-2 clinical study. This trial assessed the e...",
"url": "https://www.gurufocus.com/news/2900249/arvinas-arvn-announces-promising-phase-3-trial-results-for-vepdegestrant-arvn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BIBF.png?20",
"language": "en",
"published_at": "2025-06-01T21:45:29.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ARVN",
"name": "Arvinas, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 62.788727,
"sentiment_score": 0.168211,
"highlights": [
{
"highlight": "<em>Arvinas</em> (ARVN, Financial), in p[+311 characters]",
"sentiment": -0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+278 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+334 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+237 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+325 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Arvinas</em> <em>In[+315 characters]",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arvinas</em> <em>Inc</em> (ARVN) rec[+305 characters]",
"sentiment": -0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arvinas</em> <em>Inc</em> (ARVN) has[+162 characters]",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arvinas</em> (ARVN) Announces Promising Phase 3 Trial Results for Vepdegestrant | ARVN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "792f7702-8791-4fc5-bbc0-d439aeb0b0e1",
"title": "Arcus Biosciences (RCUS) Unveils Promising Data for Cancer Treatment | RCUS Stock News",
"description": "Arcus Biosciences (RCUS) recently showcased initial results for their investigational combination therapy, casdatifan plus cabozantinib, at the 2025 American So",
"keywords": "GuruFocus, Article, News, GuruFocus News, RCUS",
"snippet": "Arcus Biosciences (RCUS, Financial) recently showcased initial results for their investigational combination therapy, casdatifan plus cabozantinib, at the 2025 ...",
"url": "https://www.gurufocus.com/news/2900243/arcus-biosciences-rcus-unveils-promising-data-for-cancer-treatment-rcus-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BEGO.png?20",
"language": "en",
"published_at": "2025-06-01T21:30:12.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "RCUS",
"name": "Arcus Biosciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 102.662895,
"sentiment_score": 0.167056,
"highlights": [
{
"highlight": "<em>Arcus</em> <em>Biosciences</em> (RCU[+292 characters]",
"sentiment": -0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+298 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+285 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+255 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+241 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Arcus</em> <em>Bios[+274 characters]",
"sentiment": 0.9413,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arcus</em> <em>Biosciences</em> <em>[+284 characters]",
"sentiment": 0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arcus</em> <em>Biosciences</em> <em>[+150 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arcus</em> <em>Biosciences</em> (RCUS) Unveils Promising Data for Cancer Treatment | RCUS Stock News",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "1acc11e5-1a8a-403a-ae6d-a3df1cc4a828",
"title": "Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | ALLO Stock News",
"description": "Allogene Therapeutics' (ALLO) ALLO-316 shows a 31% response rate in advanced renal cell carcinoma with high CD70 expression. Four out of five patients m",
"keywords": "GuruFocus, Article, News, GuruFocus News, ALLO",
"snippet": "Allogene Therapeutics' (ALLO, Financial) ALLO-316 shows a 31% response rate in advanced renal cell carcinoma with high CD70 expression.\n\nFour out of five patien...",
"url": "https://www.gurufocus.com/news/2900184/allogene-therapeutics-provides-updated-phase-1-data-highlighting-durable-responses-with-allo316-in-heavily-pretreated-advanced-renal-cell-carcinoma-at-asco-allo-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BIIE.png?20",
"language": "en",
"published_at": "2025-06-01T16:00:23.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ALLO",
"name": "Allogene Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 66.951675,
"sentiment_score": 0.376667,
"highlights": [
{
"highlight": "<em>Allogene</em> <em>Therapeutics</em>'[+323 characters]",
"sentiment": 0.2551,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Allogene</em> <em>Therapeutics</em>,[+164 characters]",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Allogene</em> <em>Therapeutics</em> Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | ALLO Stock News",
"sentiment": 0.25,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "a5e2b474-d7c3-4885-852a-7d16b44a65ea",
"title": "Seer (SEER) Launches Groundbreaking Cancer Biomarker Study | SEER Stock News",
"description": "Seer (SEER) has initiated an ambitious study focused on discovering new blood-based biomarkers for cancer diagnostics in young adults, specifically targeting th",
"keywords": "GuruFocus, Article, News, GuruFocus News, SEER",
"snippet": "Seer (SEER, Financial) has initiated an ambitious study focused on discovering new blood-based biomarkers for cancer diagnostics in young adults, specifically t...",
"url": "https://www.gurufocus.com/news/2900262/seer-seer-launches-groundbreaking-cancer-biomarker-study-seer-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BZUB.png?20",
"language": "en",
"published_at": "2025-06-01T22:00:48.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "SEER",
"name": "Seer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 78.46973,
"sentiment_score": 0.325767,
"highlights": [
{
"highlight": "<em>Seer</em> (<em>SEER</em>, Financial)[+174 characters]",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+280 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+339 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+241 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+346 characters]",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Seer</em> <em>Inc</[+290 characters]",
"sentiment": 0.8658,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Seer</em> <em>Inc</em> (<em>SEER</em[+317 characters]",
"sentiment": 0.9022,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Seer</em> <em>Inc</em> (<em>SEER</em[+184 characters]",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Seer</em> (<em>SEER</em>) Launches Groundbreaking Cancer Biomarker Study | <em>SEER</em> Stock News",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "42a22b59-16fc-48a5-9836-c0fa55ec356d",
"title": "AstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials | AZN Stock News",
"description": "Recent trial data highlights the potential of DATROWAY, a TROP2 directed DXd antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca (AZN), in treat",
"keywords": "GuruFocus, Article, News, GuruFocus News, AZN",
"snippet": "Recent trial data highlights the potential of DATROWAY, a TROP2 directed DXd antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca (AZN, Financial...",
"url": "https://www.gurufocus.com/news/2900260/astrazenecas-azn-datroway-shows-promise-in-lung-cancer-trials-azn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C00000AGP.png?20",
"language": "en",
"published_at": "2025-06-01T22:00:33.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 36.576626,
"sentiment_score": 0.363143,
"highlights": [
{
"highlight": "Recent trial data highlights the potenti[+179 characters]",
"sentiment": -0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0A4J.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 36.57663,
"sentiment_score": 0.363143,
"highlights": [
{
"highlight": "Recent trial data highlights the potenti[+179 characters]",
"sentiment": -0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "6e668e4f-046c-4023-8bdb-c4e1b03769a0",
"title": "Merck's (MRK) Keytruda-Trodelvy Combo Shows Significant Benefits in Breast Cancer Treatment | MRK Stock News",
"description": "Merck (MRK), internationally referred to as MSD, has unveiled promising findings from a study involving its cancer drug KEYTRUDA in combination with Trodelvy. T",
"keywords": "GuruFocus, Article, News, GuruFocus News, MRK",
"snippet": "Merck (MRK, Financial), internationally referred to as MSD, has unveiled promising findings from a study involving its cancer drug KEYTRUDA in combination with ...",
"url": "https://www.gurufocus.com/news/2900240/mercks-mrk-keytrudatrodelvy-combo-shows-significant-benefits-in-breast-cancer-treatment-mrk-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000008C5.png?20",
"language": "en",
"published_at": "2025-06-01T21:15:49.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRKD.BA",
"name": "MERCK & CO INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 38.787174,
"sentiment_score": 0.0285,
"highlights": [
{
"highlight": "<em>Merck</em> (MRK, Financial), interna[+138 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+292 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+260 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+248 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+60 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.SN",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 38.7865,
"sentiment_score": 0.0285,
"highlights": [
{
"highlight": "<em>Merck</em> (MRK, Financial), interna[+138 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+292 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+260 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+248 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+60 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 38.78658,
"sentiment_score": 0.0285,
"highlights": [
{
"highlight": "<em>Merck</em> (MRK, Financial), interna[+138 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+292 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+260 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+248 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+60 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "6MK.DE",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 38.78656,
"sentiment_score": 0.0285,
"highlights": [
{
"highlight": "<em>Merck</em> (MRK, Financial), interna[+138 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+292 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+260 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+248 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+60 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.PA",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "fr",
"type": "equity",
"industry": "Healthcare",
"match_score": 38.786766,
"sentiment_score": 0.0285,
"highlights": [
{
"highlight": "<em>Merck</em> (MRK, Financial), interna[+138 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+292 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+260 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+248 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+60 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.MX",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 38.78688,
"sentiment_score": 0.0285,
"highlights": [
{
"highlight": "<em>Merck</em> (MRK, Financial), interna[+138 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+292 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+260 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+248 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+60 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "f6461fed-1f8c-43a1-9129-8685d51c96d7",
"title": "Guardant Health (GH) Reveals Key Insights on Colon Cancer Recurrence | GH Stock News",
"description": "Guardant Health (GH) has unveiled significant findings from an extensive study analyzing circulating tumor DNA (ctDNA) in colon cancer patients before chemother",
"keywords": "GuruFocus, Article, News, GuruFocus News, GH",
"snippet": "Guardant Health (GH, Financial) has unveiled significant findings from an extensive study analyzing circulating tumor DNA (ctDNA) in colon cancer patients befor...",
"url": "https://www.gurufocus.com/news/2900235/guardant-health-gh-reveals-key-insights-on-colon-cancer-recurrence-gh-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BIF0.png?20",
"language": "en",
"published_at": "2025-06-01T21:15:17.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GH",
"name": "Guardant Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 81.9498,
"sentiment_score": 0.003086,
"highlights": [
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH, F[+153 characters]",
"sentiment": -0.7351,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+294 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+277 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+252 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+316 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Guardant</em> <em>H[+258 characters]",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH) Reveals Key Insights on Colon Cancer Recurrence | GH Stock News",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
},
{
"symbol": "GH.MX",
"name": "Guardant Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 81.9407,
"sentiment_score": 0.003086,
"highlights": [
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH, F[+153 characters]",
"sentiment": -0.7351,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+294 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+277 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+252 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+316 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Guardant</em> <em>H[+258 characters]",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH) Reveals Key Insights on Colon Cancer Recurrence | GH Stock News",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "229decea-ea71-477f-b2b4-7ef6bbbf5dd8",
"title": "GILD: Gilead's Trodelvy Shows Significant Benefit in Breast Cancer Study | GILD Stock News",
"description": "Gilead Sciences (GILD) has announced promising results from a pivotal study involving Trodelvy and Keytruda in treating PD-L1+ metastatic triple-negative breast",
"keywords": "GuruFocus, Article, News, GuruFocus News, GILD",
"snippet": "Gilead Sciences (GILD, Financial) has announced promising results from a pivotal study involving Trodelvy and Keytruda in treating PD-L1+ metastatic triple-nega...",
"url": "https://www.gurufocus.com/news/2900233/gild-gileads-trodelvy-shows-significant-benefit-in-breast-cancer-study-gild-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000007VR.png?20",
"language": "en",
"published_at": "2025-06-01T21:00:37.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GILDD.BA",
"name": "GILEAD SCIENCES",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 54.513367,
"sentiment_score": -0.06848,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+327 characters]",
"sentiment": -0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+289 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+272 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+248 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+57 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 58.57052,
"sentiment_score": -0.06848,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+327 characters]",
"sentiment": -0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+298 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+281 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+257 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+66 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GIS.DE",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 58.567093,
"sentiment_score": -0.06848,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+327 characters]",
"sentiment": -0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+298 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+281 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+257 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+66 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD.MX",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 58.56688,
"sentiment_score": -0.06848,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+327 characters]",
"sentiment": -0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+298 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+281 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+257 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+66 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "9f01ec79-e7e1-4567-b21a-df84f9d1312e",
"title": "AstraZeneca (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"description": "The DESTINY-Gastric04 phase 3 study has yielded promising results for ENHERTU, an innovative HER2-targeting DXd antibody-drug conjugate crafted by Daiichi Sanky",
"keywords": "GuruFocus, Article, News, GuruFocus News, AZN",
"snippet": "The DESTINY-Gastric04 phase 3 study has yielded promising results for ENHERTU, an innovative HER2-targeting DXd antibody-drug conjugate crafted by Daiichi Sanky...",
"url": "https://www.gurufocus.com/news/2900231/astrazeneca-azn-enhertu-demonstrates-significant-survival-boost-in-gastric-cancer-trial-azn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C00000AGP.png?20",
"language": "en",
"published_at": "2025-06-01T21:00:28.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.821407,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
},
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.814663,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.814663,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZNN.MX",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.812347,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZN.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.810978,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
},
{
"symbol": "0A4J.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 49.80697,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "faeabcdf-cd48-4f4f-ac77-9f2e35e76807",
"title": "NIO's May 2025 Vehicle Deliveries Surge by 13.1% Year-Over-Year | NIO Stock News",
"description": "NIO (NIO) reported its delivery figures for May 2025, showcasing a notable growth of 13.1% compared to the same month last year. During this period, NIO success",
"keywords": "GuruFocus, Article, News, GuruFocus News, NIO",
"snippet": "NIO (NIO, Financial) reported its delivery figures for May 2025, showcasing a notable growth of 13.1% compared to the same month last year. During this period, ...",
"url": "https://www.gurufocus.com/news/2900261/nios-may-2025-vehicle-deliveries-surge-by-131-yearoveryear-nio-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BI4O.png?20",
"language": "en",
"published_at": "2025-06-01T22:00:41.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "NIO",
"name": "NIO Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 46.56025,
"sentiment_score": 0.388213,
"highlights": [
{
"highlight": "<em>NIO</em> (<em>NIO</em>, Financial) r[+201 characters]",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "By the end of May 2025, <em>NIO</em> had[+304 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+336 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+241 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+285 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>NIO</em> <em>Inc</e[+268 characters]",
"sentiment": 0.91,
"highlighted_in": "main_text"
},
{
"highlight": "The company launched the <em>NIO</em> ET[+291 characters]",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "NIO's May 2025 Vehicle Deliveries Surge by 13.1% Year-Over-Year | <em>NIO</em> Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "a111f281-d159-4db5-8736-c4ad66542e96",
"title": "XPeng (XPEV) Reports Impressive Vehicle Delivery Surge in May 2025 | XPEV Stock News",
"description": "XPeng (XPEV) reported a significant milestone in its vehicle delivery performance for May 2025. The company successfully delivered 33,525 Smart EVs during the m",
"keywords": "GuruFocus, Article, News, GuruFocus News, XPEV",
"snippet": "XPeng (XPEV, Financial) reported a significant milestone in its vehicle delivery performance for May 2025. The company successfully delivered 33,525 Smart EVs d...",
"url": "https://www.gurufocus.com/news/2900252/xpeng-xpev-reports-impressive-vehicle-delivery-surge-in-may-2025-xpev-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BXZD.png?20",
"language": "en",
"published_at": "2025-06-01T21:45:52.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "XPEV",
"name": "XPeng Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 50.851196,
"sentiment_score": 0.569173,
"highlights": [
{
"highlight": "<em>XPeng</em> (XPEV, Financial) reporte[+232 characters]",
"sentiment": 0.9118,
"highlighted_in": "main_text"
},
{
"highlight": "This achievement marks the seventh conse[+255 characters]",
"sentiment": 0.7506,
"highlighted_in": "main_text"
},
{
"highlight": "In addition, the MONA M03 Max is the ina[+108 characters]",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+277 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+330 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+235 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+216 characters]",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>XPeng</em> <em>Inc<[+247 characters]",
"sentiment": 0.7717,
"highlighted_in": "main_text"
},
{
"highlight": "<em>XPeng</em> <em>Inc</em> (XPEV) repor[+261 characters]",
"sentiment": 0.9022,
"highlighted_in": "main_text"
},
{
"highlight": "<em>XPeng</em> <em>Inc</em> (XPEV) antic[+121 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>XPeng</em> (XPEV) Reports Impressive Vehicle Delivery Surge in May 2025 | XPEV Stock News",
"sentiment": 0.5106,
"highlighted_in": "title"
}
]
},
{
"symbol": "XPEVN.MX",
"name": "XPeng Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "N/A",
"match_score": 50.848618,
"sentiment_score": 0.569173,
"highlights": [
{
"highlight": "<em>XPeng</em> (XPEV, Financial) reporte[+232 characters]",
"sentiment": 0.9118,
"highlighted_in": "main_text"
},
{
"highlight": "This achievement marks the seventh conse[+255 characters]",
"sentiment": 0.7506,
"highlighted_in": "main_text"
},
{
"highlight": "In addition, the MONA M03 Max is the ina[+108 characters]",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+277 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+330 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+235 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+216 characters]",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>XPeng</em> <em>Inc<[+247 characters]",
"sentiment": 0.7717,
"highlighted_in": "main_text"
},
{
"highlight": "<em>XPeng</em> <em>Inc</em> (XPEV) repor[+261 characters]",
"sentiment": 0.9022,
"highlighted_in": "main_text"
},
{
"highlight": "<em>XPeng</em> <em>Inc</em> (XPEV) antic[+121 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>XPeng</em> (XPEV) Reports Impressive Vehicle Delivery Surge in May 2025 | XPEV Stock News",
"sentiment": 0.5106,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "46c58e91-0214-4848-ad12-59e3fcf9701c",
"title": "Li Auto (LI) Reports Strong Vehicle Deliveries in May 2025 | LI Stock News",
"description": "Li Auto (LI) reported that it delivered 40,856 vehicles in May 2025, marking a 16.7% increase compared to the same period last year. By the end of May, the comp",
"keywords": "GuruFocus, Article, News, GuruFocus News, LI",
"snippet": "Li Auto (LI, Financial) reported that it delivered 40,856 vehicles in May 2025, marking a 16.7% increase compared to the same period last year. By the end of Ma...",
"url": "https://www.gurufocus.com/news/2900251/li-auto-li-reports-strong-vehicle-deliveries-in-may-2025-li-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BVHF.png?20",
"language": "en",
"published_at": "2025-06-01T21:45:44.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "LIAN.MX",
"name": "Li Auto Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "N/A",
"match_score": 70.52505,
"sentiment_score": 0.368944,
"highlights": [
{
"highlight": "<em>Li</em> <em>Auto</em> (LI, Financial[+303 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+286 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+348 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+245 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+309 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Li</em> <em>Auto</e[+242 characters]",
"sentiment": 0.7964,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Li</em> <em>Auto</em> <em>Inc</em> ([+282 characters]",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Li</em> <em>Auto</em> <em>Inc</em> ([+109 characters]",
"sentiment": -0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Li</em> <em>Auto</em> (LI) Reports Strong Vehicle Deliveries in May 2025 | LI Stock News",
"sentiment": 0.5106,
"highlighted_in": "title"
}
]
},
{
"symbol": "LI",
"name": "Li Auto Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 70.52484,
"sentiment_score": 0.368944,
"highlights": [
{
"highlight": "<em>Li</em> <em>Auto</em> (LI, Financial[+303 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+286 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+348 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+245 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+309 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Li</em> <em>Auto</e[+242 characters]",
"sentiment": 0.7964,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Li</em> <em>Auto</em> <em>Inc</em> ([+282 characters]",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Li</em> <em>Auto</em> <em>Inc</em> ([+109 characters]",
"sentiment": -0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Li</em> <em>Auto</em> (LI) Reports Strong Vehicle Deliveries in May 2025 | LI Stock News",
"sentiment": 0.5106,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "9d493cd3-cf5e-4593-8f68-88eb1fbc0a55",
"title": "Gilead (GILD) Presents Yescarta Study Results at ASCO 2025 | GILD Stock News",
"description": "Kite, a subsidiary of Gilead Sciences (GILD), has shared insights from a study assessing the real-world application of Yescarta for patients with relapsed or re",
"keywords": "GuruFocus, Article, News, GuruFocus News, GILD",
"snippet": "Kite, a subsidiary of Gilead Sciences (GILD, Financial), has shared insights from a study assessing the real-world application of Yescarta for patients with rel...",
"url": "https://www.gurufocus.com/news/2900245/gilead-gild-presents-yescarta-study-results-at-asco-2025-gild-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000007VR.png?20",
"language": "en",
"published_at": "2025-06-01T21:30:24.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GIS.DE",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 59.202827,
"sentiment_score": 0.16494,
"highlights": [
{
"highlight": "Kite, a subsidiary of <em>Gilead</em> <e[+312 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+298 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+281 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+257 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+66 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD.MX",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 59.20261,
"sentiment_score": 0.16494,
"highlights": [
{
"highlight": "Kite, a subsidiary of <em>Gilead</em> <e[+312 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+298 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+281 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+257 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+66 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 59.200733,
"sentiment_score": 0.16494,
"highlights": [
{
"highlight": "Kite, a subsidiary of <em>Gilead</em> <e[+312 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+298 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+281 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+257 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+66 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "2a84d2a5-ecf6-452f-b992-9e4f3e9107c8",
"title": "CGC Deadline: Rosen Law Firm Urges Canopy Growth Corporation (NASDAQ: CGC) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights",
"description": "Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Canopy Gr",
"keywords": "GuruFocus, Article, News, Business Wire, NAS:CGC",
"snippet": "Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Canopy Gro...",
"url": "https://www.gurufocus.com/news/2900257/cgc-deadline-rosen-law-firm-urges-canopy-growth-corporation-nasdaq-cgc-stockholders-with-losses-in-excess-of-100k-to-contact-the-firm-for-information-about-their-rights",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T22:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "CGC",
"name": "Canopy Growth Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 133.16637,
"sentiment_score": -0.162314,
"highlights": [
{
"highlight": "Rosen Law Firm, a global investor rights[+237 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Canopy</em> <em>Growth</em> describe[+238 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The Allegations: Rosen Law Firm is Inves[+166 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "According to the lawsuit, during the Cla[+185 characters]",
"sentiment": -0.7269,
"highlighted_in": "main_text"
},
{
"highlight": "(“Claybourne”) pre-rolled joints in [+337 characters]",
"sentiment": -0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "What Now: You may be eligible to partici[+319 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "CGC Deadline: Rosen Law Firm Urges <em>Canopy</em> <em>Growth</em> <em>Corporation</em> (<em>NASDAQ</em>: <em>CGC</em>) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "e9b37af4-46a5-4539-a9df-d4a59868c82a",
"title": "TechTarget, Inc. Investor News: If You Have Suffered Losses in TechTarget, Inc. (NASDAQ: TTGT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights",
"description": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claim",
"keywords": "GuruFocus, Article, News, Marketwired, TTGT",
"snippet": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims o...",
"url": "https://www.gurufocus.com/news/2900194/techtarget-inc-investor-news-if-you-have-suffered-losses-in-techtarget-inc-nasdaq-ttgt-you-are-encouraged-to-contact-the-rosen-law-firm-about-your-rights",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T17:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TTGT",
"name": "TechTarget, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 151.02612,
"sentiment_score": 0.12006,
"highlights": [
{
"highlight": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE)[+326 characters]",
"sentiment": -0.128,
"highlighted_in": "main_text"
},
{
"highlight": "SO WHAT: If you purchased <em>TechTarget[+226 characters]",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "WHAT IS THIS ABOUT: After market hours o[+265 characters]",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "On this news, <em>TechTarget</em> stock [+259 characters]",
"sentiment": 0.8519,
"highlighted_in": "main_text"
},
{
"highlight": "<em>TechTarget</em>, <em>Inc</em>. Investor News: If You Have Suffered Losses in <em>TechTarget</em>, <em>Inc</em>. (<em>NASDAQ</em>: <em>TTGT</em>), You Are Encouraged to Contact The Rosen Law Firm About Your Rights",
"sentiment": -0.5267,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "cee9101a-65f4-4b36-b82a-cd680ffeb013",
"title": "INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Canopy Growth Corporation and Certain Officers - CGC",
"description": "PR NewswireNEW YORK, June 1, 2025\n\n\n\nNEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Canopy",
"keywords": "GuruFocus, Article, News, PRNewswire, NAS:CGC",
"snippet": "NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Canopy Growth Corporation (\"Canopy\" or the \"Co...",
"url": "https://www.gurufocus.com/news/2900151/investor-alert-pomerantz-law-firm-announces-the-filing-of-a-class-action-against-canopy-growth-corporation-and-certain-officers-cgc",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T16:00:08.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "CGC",
"name": "Canopy Growth Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 107.622955,
"sentiment_score": 0.3288,
"highlights": [
{
"highlight": "NEW YORK, June 1, 2025 /PRNewswire/ -- P[+208 characters]",
"sentiment": 0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT:\n\nDanielle Peyton\n\nPomerantz LLP[+327 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against <em>Canopy</em> <em>Growth</em> <em>Corporation</em> and Certain Officers - CGC",
"sentiment": 0.6166,
"highlighted_in": "title"
}
]
},
{
"symbol": "WEED.TO",
"name": "Canopy Growth Corporation",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Healthcare",
"match_score": 95.33444,
"sentiment_score": 0.3288,
"highlights": [
{
"highlight": "NEW YORK, June 1, 2025 /PRNewswire/ -- P[+190 characters]",
"sentiment": 0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT:\n\nDanielle Peyton\n\nPomerantz LLP[+327 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against <em>Canopy</em> <em>Growth</em> <em>Corporation</em> and Certain Officers - CGC",
"sentiment": 0.6166,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "57fb5d02-628f-4df0-a952-df8e039858a5",
"title": "TMCI Deadline: Rosen Law Firm Urges Treace Medical Concepts, Inc. (NASDAQ: TMCI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights",
"description": "Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Treace Me",
"keywords": "GuruFocus, Article, News, Business Wire, NAS:TMCI",
"snippet": "Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Treace Med...",
"url": "https://www.gurufocus.com/news/2900114/tmci-deadline-rosen-law-firm-urges-treace-medical-concepts-inc-nasdaq-tmci-stockholders-with-losses-in-excess-of-100k-to-contact-the-firm-for-information-about-their-rights",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T16:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TMCI",
"name": "Treace Medical Concepts, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 220.48807,
"sentiment_score": 0.047525,
"highlights": [
{
"highlight": "Rosen Law Firm, a global investor rights[+245 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "The Allegations: Rosen Law Firm is Inves[+180 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "What Now: You may be eligible to partici[+332 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>TMCI</em> Deadline: Rosen Law Firm Urges <em>Treace</em> <em>Medical</em> <em>Concepts</em>, <em>Inc</em>. (<em>NASDAQ</em>: <em>TMCI</em>) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "2293c64d-10c8-4a1e-9e8a-0ec1d569b1ce",
"title": "ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Open Lending Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action -- LPRO",
"description": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Open Lending Corpora",
"keywords": "GuruFocus, Article, News, Marketwired, LPRO",
"snippet": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Open Lending Corporatio...",
"url": "https://www.gurufocus.com/news/2900110/rosen-a-trusted-and-leading-law-firm-encourages-open-lending-corporation-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-lpro",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T15:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "LPRO",
"name": "Open Lending Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 83.55581,
"sentiment_score": 0.490125,
"highlights": [
{
"highlight": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE)[+305 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "SO WHAT: If you purchased <em>Open</em> [+295 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "To join the <em>Open</em> <em>Lending</e[+318 characters]",
"sentiment": -0.0717,
"highlighted_in": "main_text"
},
{
"highlight": "ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages <em>Open</em> <em>Lending</em> <em>Corporation</em> Investors to Secure Counsel Before Important Deadline in Securities Class Action -- LPRO",
"sentiment": 0.9029,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "60d70c34-f972-4009-a399-d4dce9d3dad1",
"title": "Dell (DELL) Under Federal Scrutiny Amid Spending Review",
"description": "Summary Highlights:\n The U.S. initiates a federal spending review impacting contracts with tech companies like Dell Technologies (DELL). Analysts predict a si",
"keywords": "GuruFocus, Article, News, GuruFocus News, DELL",
"snippet": "Summary Highlights:\n\nThe U.S. initiates a federal spending review impacting contracts with tech companies like Dell Technologies (DELL, Financial).\n\nAnalysts pr...",
"url": "https://www.gurufocus.com/news/2900256/dell-dell-under-federal-scrutiny-amid-spending-review",
"image_url": "https://static.gurufocus.com/logos/0C0000BIA4.png?20",
"language": "en",
"published_at": "2025-06-01T21:55:21.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "DELL",
"name": "Dell Technologies Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 45.945442,
"sentiment_score": 0.1601,
"highlights": [
{
"highlight": "Summary Highlights:\n\nThe U.S. initiates [+238 characters]",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Federal Spending Review Expands to Tech [+208 characters]",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analyst Predictions\n\nAnalyst[+323 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "For more in-depth estimate data, visit t[+288 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "GuruFocus GF Value Insights\n\nAccording t[+213 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed information can be accesse[+78 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "3c32ccbb-50e8-414d-a546-0f91f65ab9e7",
"title": "UiPath (PATH) Sees Price Target Increase Amid Execution Stability | PATH Stock News",
"description": "Bank of America has adjusted its price target for UiPath (PATH), raising it from $10 to $12 while maintaining an Underperform rating on the stock. The upgrade f",
"keywords": "GuruFocus, Article, News, GuruFocus News, PATH",
"snippet": "Bank of America has adjusted its price target for UiPath (PATH, Financial), raising it from $10 to $12 while maintaining an Underperform rating on the stock. Th...",
"url": "https://www.gurufocus.com/news/2900190/uipath-path-sees-price-target-increase-amid-execution-stability-path-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T16:45:11.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "PATH",
"name": "UiPath Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 88.8833,
"sentiment_score": 0.419711,
"highlights": [
{
"highlight": "Bank of America has adjusted its price t[+243 characters]",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+286 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+344 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+245 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+277 characters]",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>UiPath</em> <em>Inc[+183 characters]",
"sentiment": 0.8481,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UiPath</em> <em>Inc</em> (<em>PATH</[+325 characters]",
"sentiment": 0.8402,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UiPath</em> <em>Inc</em> (<em>PATH</[+198 characters]",
"sentiment": -0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UiPath</em> (<em>PATH</em>) Sees Price Target Increase Amid Execution Stability | <em>PATH</em> Stock News",
"sentiment": 0.3182,
"highlighted_in": "title"
}
]
},
{
"symbol": "P2AT34.SA",
"name": "UiPath Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Technology",
"match_score": 55.114166,
"sentiment_score": 0.419711,
"highlights": [
{
"highlight": "Bank of America has adjusted its price t[+234 characters]",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+277 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+326 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+236 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+259 characters]",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>UiPath</em> <em>Inc[+174 characters]",
"sentiment": 0.8481,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UiPath</em> <em>Inc</em> (PATH) laun[+316 characters]",
"sentiment": 0.8402,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UiPath</em> <em>Inc</em> (PATH) main[+189 characters]",
"sentiment": -0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UiPath</em> (PATH) Sees Price Target Increase Amid Execution Stability | PATH Stock News",
"sentiment": 0.3182,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "588f6ccd-1752-412b-a08b-25b8cf2afe91",
"title": "BofA Adjusts Price Target for Blue Owl Capital (OBDC) Amid Mixed Q1 Results | OBDC Stock News",
"description": "BofA has revised its price target for Blue Owl Capital (OBDC), reducing it from $16.25 to $15.50 while maintaining a Buy rating on the stock. The first quarter",
"keywords": "GuruFocus, Article, News, GuruFocus News, OBDC",
"snippet": "BofA has revised its price target for Blue Owl Capital (OBDC, Financial), reducing it from $16.25 to $15.50 while maintaining a Buy rating on the stock. The fir...",
"url": "https://www.gurufocus.com/news/2900188/bofa-adjusts-price-target-for-blue-owl-capital-obdc-amid-mixed-q1-results-obdc-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T16:30:43.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "OWL",
"name": "Blue Owl Capital Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 90.30485,
"sentiment_score": 0.254871,
"highlights": [
{
"highlight": "BofA has revised its price target for <e[+282 characters]",
"sentiment": -0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+297 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+294 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+257 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+285 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Blue</em> <em>Owl</[+295 characters]",
"sentiment": 0.9153,
"highlighted_in": "main_text"
},
{
"highlight": "BofA Adjusts Price Target for <em>Blue</em> <em>Owl</em> <em>Capital</em> (OBDC) Amid Mixed Q1 Results | OBDC Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "b94ff295-5a59-4381-81e1-5d6f4fc16cbc",
"title": "Campbell Soup (CPB) Faces Earnings Decline Amid Industry Pressures",
"description": "Key Takeaways:\n Campbell Soup Company's (CPB) fiscal third-quarter profits are projected to decrease by 13% year-over-year. Analysts express concerns rega",
"keywords": "GuruFocus, Article, News, GuruFocus News, CPB",
"snippet": "Key Takeaways:\n\nCampbell Soup Company's (CPB, Financial) fiscal third-quarter profits are projected to decrease by 13% year-over-year.\n\nAnalysts express concern...",
"url": "https://www.gurufocus.com/news/2900090/campbell-soup-cpb-faces-earnings-decline-amid-industry-pressures",
"image_url": "https://static.gurufocus.com/logos/0C00000746.png?20",
"language": "en",
"published_at": "2025-06-01T13:55:29.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "CPB",
"name": "Campbell Soup Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 116.2067,
"sentiment_score": 0.255783,
"highlights": [
{
"highlight": "Key Takeaways:\n\n<em>Campbell</em> <em>So[+327 characters]",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast for <em>Ca[+297 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Consensus Rating and GF Value\n\nThe senti[+229 characters]",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "According to GuruFocus, the estimated GF[+183 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "For a more comprehensive understanding o[+254 characters]",
"sentiment": 0.1689,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Campbell</em> <em>Soup</em> (CPB) Faces Earnings Decline Amid Industry Pressures",
"sentiment": -0.3182,
"highlighted_in": "title"
}
]
},
{
"symbol": "CSC.DE",
"name": "Campbell Soup Company",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 95.03115,
"sentiment_score": 0.255783,
"highlights": [
{
"highlight": "Key Takeaways:\n\n<em>Campbell</em> <em>So[+327 characters]",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast for <em>Ca[+279 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Consensus Rating and GF Value\n\nThe senti[+229 characters]",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "According to GuruFocus, the estimated GF[+183 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "For a more comprehensive understanding o[+254 characters]",
"sentiment": 0.1689,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Campbell</em> <em>Soup</em> (CPB) Faces Earnings Decline Amid Industry Pressures",
"sentiment": -0.3182,
"highlighted_in": "title"
}
]
},
{
"symbol": "CPB.MX",
"name": "Campbell Soup Company",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 95.02873,
"sentiment_score": 0.255783,
"highlights": [
{
"highlight": "Key Takeaways:\n\n<em>Campbell</em> <em>So[+327 characters]",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast for <em>Ca[+279 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Consensus Rating and GF Value\n\nThe senti[+229 characters]",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "According to GuruFocus, the estimated GF[+183 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "For a more comprehensive understanding o[+254 characters]",
"sentiment": 0.1689,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Campbell</em> <em>Soup</em> (CPB) Faces Earnings Decline Amid Industry Pressures",
"sentiment": -0.3182,
"highlighted_in": "title"
}
]
},
{
"symbol": "0HST.L",
"name": "Campbell Soup Company",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 95.02503,
"sentiment_score": 0.255783,
"highlights": [
{
"highlight": "Key Takeaways:\n\n<em>Campbell</em> <em>So[+327 characters]",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast for <em>Ca[+279 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Consensus Rating and GF Value\n\nThe senti[+229 characters]",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "According to GuruFocus, the estimated GF[+183 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "For a more comprehensive understanding o[+254 characters]",
"sentiment": 0.1689,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Campbell</em> <em>Soup</em> (CPB) Faces Earnings Decline Amid Industry Pressures",
"sentiment": -0.3182,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "ab939c56-4a0e-4ffb-8c9a-69ce49931529",
"title": "Jim Cramer and Wall Street Are Bullish on Fair Isaac Corporation (FICO)",
"description": "We recently published a list of 10 Stocks on Jim Cramer and Wall Street’s Radar. In this article, we are going to take a look at where Fair Isaac Corporation (NYSE:FICO) stands against other stocks on Jim Cramer and Wall Street’s radar. Discussing Fair Isaac Corporation (NYSE:FICO) at the end of April, Cramer made the […]",
"keywords": "Fair Isaac Corporation, Jim Cramer, Wall Street, FICO score",
"snippet": "We recently published a list of 10 Stocks on Jim Cramer and Wall Street’s Radar. In this article, we are going to take a look at where Fair Isaac Corporation ...",
"url": "https://finance.yahoo.com/news/jim-cramer-wall-street-bullish-215155165.html",
"image_url": "https://s.yimg.com/ny/api/res/1.2/4S7FOXGAMWpn4NRuAEBNEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/783f0cd7cc8e03a4456a414e8b3806fe",
"language": "en",
"published_at": "2025-06-01T21:51:55.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "FICO",
"name": "Fair Isaac Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 151.2194,
"sentiment_score": 0.426775,
"highlights": [
{
"highlight": "In this article, we are going to take a [+383 characters]",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "It’s called <em>Fair</em> <em>Isaac</e[+344 characters]",
"sentiment": 0.8225,
"highlighted_in": "main_text"
},
{
"highlight": "Baird expects <em>Fair</em> <em>Isaac</e[+314 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "Jim Cramer and Wall Street Are Bullish on <em>Fair</em> <em>Isaac</em> <em>Corporation</em> (FICO)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "8b5737b4-c471-4ddc-9f22-3f163abbdfd5",
"title": "A dying demographic: how Murdoch is slowly killing the Liberal Party",
"description": "Rupert Murdoch's News Corporation is dragging the Liberal Party down",
"keywords": "",
"snippet": "Rupert Murdoch’s News Corporation is dragging the Liberal Party down “one funeral at a time”. And visa-versa. Michael Pascoe reports.\n\nTwo swimmers strugg...",
"url": "https://michaelwest.com.au/a-dying-demographic-how-murdoch-is-slowly-killing-the-liberal-party/",
"image_url": "https://michaelwest.com.au/wp-content/uploads/2020/11/rupert.surgery.jpg",
"language": "en",
"published_at": "2025-06-01T21:51:42.000000Z",
"source": "michaelwest.com.au",
"relevance_score": null,
"entities": [
{
"symbol": "NWSA",
"name": "News Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 5.030231,
"sentiment_score": -0.8068,
"highlights": [
{
"highlight": "Rupert Murdoch’s <em>News</em> <em>Cor[+240 characters]",
"sentiment": -0.8068,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NWS",
"name": "News Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 5.030231,
"sentiment_score": -0.8068,
"highlights": [
{
"highlight": "Rupert Murdoch’s <em>News</em> <em>Cor[+240 characters]",
"sentiment": -0.8068,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "ad2f8a77-36cc-4f90-94f7-a2528d120da3",
"title": "Jim Cramer and Wall Street Are Bullish on Capital One Financial Corporation (NYSE:COF)",
"description": "We recently published a list of 10 Stocks on Jim Cramer and Wall Street’s Radar. In this article, we are going to take a look at where Capital One Financial Corporation (NYSE:COF) stands against other stocks on Jim Cramer and Wall Street’s radar. During April 24’s episode of Squawk on the Street, Cramer made the […]",
"keywords": "Jim Cramer, Capital One, Squawk on the Street, Wall Street",
"snippet": "We recently published a list of 10 Stocks on Jim Cramer and Wall Street’s Radar. In this article, we are going to take a look at where Capital One Financial C...",
"url": "https://finance.yahoo.com/news/jim-cramer-wall-street-bullish-214554280.html",
"image_url": "https://s.yimg.com/ny/api/res/1.2/UjrpUsoScvW7wYSpjuWxeg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/5adbb08e5715b3042f63322c02832581",
"language": "en",
"published_at": "2025-06-01T21:45:54.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "COF",
"name": "Capital One Financial Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 161.13374,
"sentiment_score": 0.16375,
"highlights": [
{
"highlight": "In this article, we are going to take a [+381 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Capital</em> <em>One</em> <em>Financ[+305 characters]",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "On May 21, BofA analyst Mihir Bhatia inc[+157 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Jim Cramer and Wall Street Are Bullish on <em>Capital</em> <em>One</em> <em>Financial</em> <em>Corporation</em> (<em>NYSE:COF</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "e7190a9d-4bef-4bb1-a290-9b3bd0aba658",
"title": "AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News",
"description": "AstraZeneca (AZN) announced encouraging findings from the MATTERHORN Phase III trial, highlighting that perioperative treatment with its drug IMFINZI, when comb",
"keywords": "GuruFocus, Article, News, GuruFocus News, AZN",
"snippet": "AstraZeneca (AZN, Financial) announced encouraging findings from the MATTERHORN Phase III trial, highlighting that perioperative treatment with its drug IMFINZI...",
"url": "https://www.gurufocus.com/news/2900246/astrazeneca-azn-reports-positive-phase-iii-trial-results-for-imfinzi-azn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C00000AGP.png?20",
"language": "en",
"published_at": "2025-06-01T21:30:33.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 51.043594,
"sentiment_score": 0.512388,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) an[+267 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News",
"sentiment": 0.5574,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 51.035656,
"sentiment_score": 0.512388,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) an[+267 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News",
"sentiment": 0.5574,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "3a514686-6828-4825-8b64-2bbded0d789a",
"title": "AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"description": "AstraZeneca (AZN) has announced promising outcomes from its SERENA-6 Phase III clinical trial, highlighting the efficacy of camizestrant when paired with a cycl",
"keywords": "GuruFocus, Article, News, GuruFocus News, AZN",
"snippet": "AstraZeneca (AZN, Financial) has announced promising outcomes from its SERENA-6 Phase III clinical trial, highlighting the efficacy of camizestrant when paired ...",
"url": "https://www.gurufocus.com/news/2900242/astrazeneca-azn-reports-promising-phase-iii-trial-results-for-camizestrant-azn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C00000AGP.png?20",
"language": "en",
"published_at": "2025-06-01T21:16:08.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 50.677715,
"sentiment_score": 0.49295,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) ha[+174 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 50.670788,
"sentiment_score": 0.49295,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) ha[+174 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 50.670788,
"sentiment_score": 0.49295,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) ha[+174 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZNN.MX",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 50.668396,
"sentiment_score": 0.49295,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) ha[+174 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZN.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "Healthcare",
"match_score": 50.66698,
"sentiment_score": 0.49295,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) ha[+174 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "0A4J.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 50.662872,
"sentiment_score": 0.49295,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) ha[+174 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "837810ab-1dd5-4dc2-b289-a4ac670e543a",
"title": "AstraZeneca's IMFINZI Shows Promising Results in Phase III MATTERHORN Trial | AZN stock news",
"description": "Summary AstraZeneca PLC (AZN) announced positive results from the MATTERHORN Phase III trial, revealing that perioperative treatment with IMFINZI® (durvalumab)",
"keywords": "GuruFocus, Article, News, GuruFocus News, AZN",
"snippet": "Summary\n\nAstraZeneca PLC (AZN, Financial) announced positive results from the MATTERHORN Phase III trial, revealing that perioperative treatment with IMFINZI® ...",
"url": "https://www.gurufocus.com/news/2900105/astrazenecas-imfinzi-shows-promising-results-in-phase-iii-matterhorn-trial-azn-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T14:01:00.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.968624,
"sentiment_score": 0.2979,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+332 characters]",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+236 characters]",
"sentiment": -0.8434,
"highlighted_in": "main_text"
},
{
"highlight": "The significant improvement in EFS and t[+277 characters]",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.968416,
"sentiment_score": 0.2979,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+332 characters]",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+236 characters]",
"sentiment": -0.8434,
"highlighted_in": "main_text"
},
{
"highlight": "The significant improvement in EFS and t[+277 characters]",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.968176,
"sentiment_score": 0.2979,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+332 characters]",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+236 characters]",
"sentiment": -0.8434,
"highlighted_in": "main_text"
},
{
"highlight": "The significant improvement in EFS and t[+277 characters]",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZNN.MX",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.96664,
"sentiment_score": 0.2979,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+332 characters]",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+236 characters]",
"sentiment": -0.8434,
"highlighted_in": "main_text"
},
{
"highlight": "The significant improvement in EFS and t[+277 characters]",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZN.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.966484,
"sentiment_score": 0.2979,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+332 characters]",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+236 characters]",
"sentiment": -0.8434,
"highlighted_in": "main_text"
},
{
"highlight": "The significant improvement in EFS and t[+277 characters]",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0A4J.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 24.966322,
"sentiment_score": 0.2979,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+332 characters]",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+236 characters]",
"sentiment": -0.8434,
"highlighted_in": "main_text"
},
{
"highlight": "The significant improvement in EFS and t[+277 characters]",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "215f98a6-7e6d-4ab6-86a6-8a194e4e8230",
"title": "AstraZeneca's Camizestrant Shows Promising Results in SERENA-6 Phase III Trial | AZN stock news",
"description": "Summary AstraZeneca PLC (AZN) announced positive results from the SERENA-6 Phase III trial, demonstrating that camizestrant, in combination with a cyclin-depend",
"keywords": "GuruFocus, Article, News, GuruFocus News, AZN",
"snippet": "Summary\n\nAstraZeneca PLC (AZN, Financial) announced positive results from the SERENA-6 Phase III trial, demonstrating that camizestrant, in combination with a c...",
"url": "https://www.gurufocus.com/news/2900104/astrazenecas-camizestrant-shows-promising-results-in-serena6-phase-iii-trial-azn-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T14:00:50.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.555803,
"sentiment_score": -0.20015,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+318 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+261 characters]",
"sentiment": -0.8591,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.555637,
"sentiment_score": -0.20015,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+318 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+261 characters]",
"sentiment": -0.8591,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.555426,
"sentiment_score": -0.20015,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+318 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+261 characters]",
"sentiment": -0.8591,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZNN.MX",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.553911,
"sentiment_score": -0.20015,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+318 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+261 characters]",
"sentiment": -0.8591,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZN.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.55378,
"sentiment_score": -0.20015,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+318 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+261 characters]",
"sentiment": -0.8591,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0A4J.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 22.553642,
"sentiment_score": -0.20015,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+318 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+261 characters]",
"sentiment": -0.8591,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "41e0af8d-674d-4403-8078-de6cc4e13997",
"title": "Protagonist Therapeutics (PTGX): Promising Phase 3 Results for Rusfertide | PTGX Stock News",
"description": "Protagonist Therapeutics (PTGX), in collaboration with Takeda, has announced encouraging outcomes from its Phase 3 VERIFY trial. This study evaluated rusfertide",
"keywords": "GuruFocus, Article, News, GuruFocus News, PTGX",
"snippet": "Protagonist Therapeutics (PTGX, Financial), in collaboration with Takeda, has announced encouraging outcomes from its Phase 3 VERIFY trial. This study evaluated...",
"url": "https://www.gurufocus.com/news/2900241/protagonist-therapeutics-ptgx-promising-phase-3-results-for-rusfertide-ptgx-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000B4TS.png?20",
"language": "en",
"published_at": "2025-06-01T21:15:57.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "PTGX",
"name": "Protagonist Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 85.031105,
"sentiment_score": 0.051475,
"highlights": [
{
"highlight": "<em>Protagonist</em> <em>Therapeutics</e[+250 characters]",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+304 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+299 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Protagonist</em> <em>Therapeutics</em> (PTGX): Promising Phase 3 Results for Rusfertide | PTGX Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "us",
"total_documents": 520,
"sentiment_avg": 0.20896216296170633
}
]
}
Other details
Entity count
- 32,649